Aluminium/magnesium hydroxide caused a 25% reduction in the bioavailability of zalcitabine. The changes are moderate and of uncertain
clinical importance.
The manufacturer of zalcitabine recommends that it should not be taken at the same time as aluminium/magnesium-containing
antacids. A separation of 2 to 3 hours is usually sufficient with other similar interactions.